Document is current
Any future updates will be listed below
-
Authors
Zhang, David K. Y. https://orcid.org/0000-0002-6999-6454
Adu-Berchie, Kwasi https://orcid.org/0000-0002-1959-6794
Iyer, Siddharth
Liu, Yutong
Cieri, Nicoletta https://orcid.org/0000-0003-1340-6272
Brockman, Joshua M.
Neuberg, Donna https://orcid.org/0000-0003-2566-3145
Wu, Catherine J. https://orcid.org/0000-0002-3348-5054
Mooney, David J. https://orcid.org/0000-0001-6299-1194
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA244726)
U.S. Department of Health & Human Services | U.S. Food and Drug Administration (5R01FD006589)
- License Information
-
More Information
Article History
Received: 26 April 2022
Accepted: 16 January 2023
First Online: 31 January 2023
Competing interests
: D.J.M. is an inventor on patent applications Harvard University has filed in relation to the aAPC-ms technology. That intellectual property has been licensed to Lyell Immunopharma, and D.J.M. has stock in Lyell Immunopharma. C.J.W. holds equity in BioNTech. The remaining authors declare no competing interests.
